Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the fir...
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuxi...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (o...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Fa...
Shuttle Pharmaceuticals Holdings, Inc. a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson&rs...
In an interaction with BioPharma BoardRoom, Saurabh Singal, CEO & Founder of MoleculeAI, discusses how their generative AI-driven tools...
Viatris Inc. (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of ceneri...
A2A Pharmaceuticals, Inc. ("A2A" or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (af...
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...
© 2025 Biopharma Boardroom. All Rights Reserved.
